Dr Paul Richardson presents the results of a phase 3 DETERMINATION trial using Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM). 

The trial used patients with NDMM aged 18-65, who were randomly assigned to receive 3 RVd cycles, stem cell mobilisation, and then 5 more RVd cycles (Arm A) or IV melphalan 200 mg/m2 + ASCT and 2 RVd cycles (Arm B). Both arms received R maintenance until progression or intolerance. The primary endpoint was PFS (90% power to detect PFS hazard ratio [HR] of 1.43 [Arm A vs. B] with α = 0.05 on stratified two-sided log-rank test; full information: 329 events in 720 patients). Data cut-off was Dec 10, 2021.

Dr Richardson summarises the results by stating Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance prolongs disease control and improves survival for newly diagnosed multiple myeloma patients.

Watch Dr Richardson's interview on the study here

Watch Dr Gralow comment on the study here

Read the news article here